SPSabino De Placido

Sabino De Placido

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sabino De Placido has a total of 127 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Shifting from a Biological-Agnostic Approach to a Molecular-Driven Strategy in Rare Cancers: Ewing Sarcoma Archetype

    by Aldo Caltavituro, Roberto Buonaiuto, Erica Pietroluongo, Rocco Morra, Fabio Salomone, Pietro De Placido, Martina Pagliuca, Angelo Vaia, Margaret Ottaviano, Marianna Tortora, et al.

    Sarcomas of the thoracic cavity are rare entities that predominantly affect children and young adults. They can be very heterogeneous encompassing several different histological entities. Ewing Sarcoma (ES) can potentially arise from every bone, soft tissue, or visceral site in the body. However, it represents an extremely rare finding when it affects the thoracic cavity. It represents the second most frequent type of thoracic sarcoma, after chondrosarcoma. ES arises more frequently in sites that differ from the thoracic cavity, but it displays the same biological features and behavior of extra-thoracic ones. Current management of ES often requires a multidisciplinary treatment approach including surgery, radiotherapy, and systemic therapy, as it can guarantee local and distant disease control, at least transiently, although the long-term outcome remains poor. Unfortunately, due to the paucity of clinical trials purposely designed for this rare malignancy, there are no optimal strategies that can be used for disease recurrence. As a result of its complex biological features, ES might be suitable for emerging biology-based therapeutic strategies. However, a deeper understanding of the molecular mechanisms driving tumor growth and treatment resistance, including those related to oncogenic pathways, epigenetic landscape, and immune microenvironment, is necessary in order to develop new valid therapeutic opportunities. Here, we provide an overview of the most recent therapeutic advances for ES in both the preclinical and clinical settings. We performed a review of the current available literature and of the ongoing clinical trials focusing on new treatment strategies, after failure of conventional multimodal treatments.


  • Open Access

    It is no longer the time to disregard thyroid metastases from breast cancer: a case report and review of the literature

    by Matilde Pensabene, Brigida Stanzione, Ivana Cerillo, Giuseppe Ciancia, Immacolata Cozzolino, Raffaella Ruocco, Caterina Condello, Giuseppe Di Lorenzo, Mario Giuliano, Valeria Forestieri, et al.

    Metastases to the thyroid gland are more frequent than previously thought, although most of them are occult or not clinically relevant. Overall, only 42 cases of metastases to thyroid from breast cancer have been reported thus far. Here we report the case of a patient with breast cancer metastatic to the thyroid. We also review the 42 previously reported cases (published between 1962 and 2012). This is the first review about metastases to thyroid gland from breast cancer. A 64-year-old woman of Caucasian origin was diagnosed with a lobular invasive carcinoma of the breast (luminal A, stage II). She received adjuvant chemotherapy, followed by endocrine therapy. During follow-up, fine-needle cytology of a thyroid nodule revealed malignant cells that were estrogen-positive, which suggested a diagnosis of metastases to the thyroid. Imaging did not reveal any other metastatic site and showed only enlargement of the left thyroid lobe and an inhomogeneous pattern of colloid and cystic degeneration and calcifications. The patient underwent left hemithyroidectomy. Histology of thyroid tissue showed a colloid goitre containing dispersed small atypical neoplastic cells with eccentric nuclei. Immunohistochemistry showed cytokeratin-19 and oestrogen receptor, but not tireoglobulin, e-cadherin or cytokeratin-7, thereby confirming metastases from a lobular breast carcinoma. Hormonal treatment is ongoing. This case report and first review of the literature on metastases to thyroid from breast cancer highlight the importance of a correct early diagnostic work-up in such cases. Indeed, a primary lesion should be distinguished from metastases given the different treatment protocol related to primary cancer and the clinical impact on prognosis.


  • Characteristics of disease activity able to identify risk categories and probability to respond to first-line endocrine therapy (ET) in HR+ve/HER2-ve metastatic breast cancer (MBC) patients (pts): Dream or reality? Evaluation of a composite risk score in a subgroup population of the GIM 13-AMBRA study.

    by Giorgio Mustacchi, Marina Elena Cazzaniga, Monica Giordano, Ornella Garrone, Alessandra Beano, Lucia Del Mastro, Lorenzo Livi, Laura Iezzi, Andrea Michelotti, Anna Turletti, et al.

    1049 Background: The appropriate choice of 1st-line therapy in HR+ve/HER2-ve MBC pts is becoming more complicated since the data of front-line Fulvestrant and CDK 4/6 Inhibitors have been released. In the absence of predictive biomarkers of tumor response, one possible option is the recently proposed “composite score” (Schmid, ESMO 2016), composed by visceral tumor burden (VTB) and Disease-Free-Interval (DFI) to identify risk categories and the probability of response to ET or chemotherapy (CHT). Aim of the present analysis is to describe the choices of 1st-line treatment and the response rate, according to the mentioned score in a population of HR+/HER2-ve MBC. Methods: We used data of the HR+ve pts of the AMBRA study, a longitudinal cohort study, describing the choice of first and subsequent lines of treatment in HER2-ve MBC pts (SABCS 2016 P5-15-07 & P5-14-09). Using median DFI and VTB three categories of risk have been identified: Low (DFI > 24 months & VTB-), Intermediate (DFI £ 24 months & VTB- or DFI > 24 months & VTB+) and High (DFI £ 24 months & VTB+). This analysis describes the choices of 1st-line therapy and relative response rate according to these risk categories. Results: So far, 791/1500 pts have been registered into the AMBRA study, 673 of them (85%) with HR+ MBC and 659 (83.3%) are evaluable for this analysis. Risk categories and response to therapy are detailed in the table below. Conclusions: No conclusion can be done regarding the “High Risk” group because of the low number of pts treated with ET alone. Regarding the “Low” and “Intermediate” risk categories, we can conclude that the proposed “composite risk score” doesn’t seem to discriminate MBC patients who could be treated with ET alone or with a more aggressive treatment, at least in terms of response rate. [Table: see text]

  • Phase 3 randomized study of adjuvant anastrozole (A), exemestane (E), or letrozole (L) with or without tamoxifen (T) in postmenopausal women with hormone-responsive (HR) breast cancer: The FATA-GIM3 trial.

    by Francesco Perrone, Ciro Gallo, Michele De Laurentiis, Giancarlo Bisagni, Grazia Arpino, Maria Giuseppa Sarobba, Ferdinando Riccardi, Antonio Russo, Lucia Del Mastro, Alessio Aligi Cogoni, et al.

    515 Background: Uncertainty still exists regarding the optimal schedule of adjuvant treatment of breast cancer with aromatase inhibitors (AI) and no trial has ever compared all the three AI. Methods: FATA-GIM3 is a multicenter, open label, 2x3 factorial phase 3 randomized study of adjuvant A, E and L upfront (UP - for 5 years) or sequentially (SEQ - for 3 years after 2 years of T) in postmenopausal HR breast cancer pts. Two comparisons were planned: UP vs SEQ and A vs E vs L. DFS (including local or distant relapse, second breast or non-breast cancer, DCIS and death, whichever came first) was the primary end-point; 2% at 5 yrs (corresponding to a HR of 0.79) was defined as the minimum difference required to declare superiority of UP vs SEQ. With two-tailed alfa 0.05, power 80%, 669 events and the enrolment of 3600 patients were planned. Following Data Monitoring Committee advice, final analysis was performed after 5yrs median follow-up. For each comparison a Cox regression model was applied adjusted by stratification factors and stratified by the other treatment factor. Analyses were based on intention-to-treat. Results: from 3/2007 to 7/2012, 3697 patients were enrolled at 76 centres. Median age 64, pT1 69.7% , pN0 64.3%, ER and PgR positive 88.9%, HER2 positive 8.9%, previous chemotherapy 38.3%. At 60 months median follow-up, 401 events were reported. 5yrs DFS was 89.8 with UP and 88.5 with SEQ (delta 1.32%, 95% CI -0.90-3.54; HR 0.89, 95% CI 0.73-1.08; P=0.23). 5yrs DFS was 90.0 with A, 88.0 with E and 89.4 with L (P=0.19). Conclusions: in the FATA-GIM3 trial there is a small non statistically significant DFS advantage for UP vs SEQ. No significant difference is evident among the three AI. Supported by the FARM5K3MEE AIFA grant from the Italian Drug Agency. Clinical trial information: NCT00541086.


  • Development and validation of a new prognostic score on 4,646 patients with luminal-like breast cancer (BC) enrolled in 7 randomized prospective trials.

    by Caterina Fontanella, Bianca Lederer, Lucia Del Mastro, Carsten Denkert, Sabino De Placido, Claus Hanusch, Francesco Cognetti, Jens Bodo Huober, Michele De Laurentiis, Christian Jackisch, et al.

    529 Background: At the 2014 ASCO meeting we presented the prognostic STAR score, designed in a dataset of 2,248 pts with low/intermediate grade Lum like BC (HER2-/estrogen receptor [ER]+/G1-2) combining tumor stage (AJCC Cancer Staging 7), progesterone receptor [PR] status, and age at baseline. In this study we included pts with high grade Lum like BC in the neoadjuvant dataset and validated the STAR score in the adjuvant GIM2 trial. Methods: EXPLORATORY COHORT (EC): 3,036 Lum like BC (HER2-/ER+/any grade) pts enrolled in 6 prospective randomized trials and treated with anthracycline-taxane based neoadjuvant therapy. VALIDATION COHORT (VC): 1,610 pts with Lum like BC from the 2x2 factorial randomized GIM2 trial (Del Mastro L, Lancet 2015) investigating dose-dense chemotherapy (CT) and the of addition of 5-FU to epirubicin-cyclophosphamide regimen. All patients received adjuvant endocrine treatment. We used uni/multivariate Cox regression analyses to explore the effect of the score on disease free (DFS) and overall survival (OS). Results: In the EC, multivariate analysis adjusted for CPS+EG score (Mittendorf EA, JCO 2011), CT density, and pCR (ypT0/is ypN0) demonstrated that the STAR score added significant independent information on DFS (p= .007) and OS (p= .002). In the VC, the STAR score added similar prognostic information after adjustment for tumor grade, Ki67 (cut off 20%), and CT density (DFS p< .001; OS p <.001). Multivariate analysis hazard ratios (HR) are shown in the table. Conclusions: The STAR score using stage at diagnosis, PR status and age discriminates Lum like BC with worse prognosis, receiving (neo)adjuvant CT and ET.

  • Breast cancer subtypes according to body mass index and insulin resistance.

    by Grazia Arpino, Anna Crispo, Mario Giuliano, Carmine De Angelis, Maria Grimaldi, Ernesta Cavalcanti, Flaviano Di Paola, Immacolata Capasso, Emanuela Esposito, Massimiliano D'Aiuto, et al.

    571 Background: High body mass index (BMI) is considered a risk factor for breast cancer (BC) onset and is correlated with bad prognosis and resistance to endocrine therapy in BC patients. Obesity is also cause of insulin resistance (IR), often associated to resistance to anti human epidermal growth factor receptor (HER) inhibitors. The aim of the present study was to assess the association of BMI levels and IR with BC immunohistochemically-defined subtypes. Methods: One thousand consecutive post-menopausal patients with early BC were included in our study. Clinical, metabolic and tumor characteristics were prospectively collected at the time of diagnosis. IR was defined by the homeostatic model assessment (HOMA), with a cut off value to define IR ≥ 3,4. BMI was categorized as low: ≤25; intermediate: 26-30; high: >25. Data were analysed by logistic regression model. Results: Patients with luminal (A and B) BC were more likely to be overweight (BMI = 26-30) (OR=2.96 95% CI 1.53-5.74; p=0.006) although they had low HOMA scores (< 3.4) (OR=0.57 95% CI 0.35-0.93; p=0.02). In contrast, patients with HER2+ subtype were at increased risk for elevated HOMA score (OR= 2.36 95% CI 1.27-4.4; p=0.007), whereas the association with BMI was not statistically significant. In additional, no significant association was found between triple negative (TN) BC and anthropometric and metabolic variables. Conclusions: Our data suggest that high BMI may be associated with endocrine sensitive BC, whereas high HOMA score, may be more frequent in patients with HER2+ subtype. These findings support the hypothesis that high estrogen exposure of breast tissue in women with higher BMI may drive growth of luminal cancers while insulin an resistance environment may increase the risk of growth factor receptor-dependent BC. If further confirmed, our data suggests that body weight reduction and glycemic control, respectively in these two subsets of women may help to prevent cancer development.

  • Open Access

    Randomised phase 3 open-label trial of first-line treatment with gemcitabine in association with docetaxel or paclitaxel in women with metastatic breast cancer: a comparison of different schedules and treatments

    by Lucia Del Mastro, Alessandra Fabi, Mauro Mansutti, Michele De Laurentiis, Antonio Durando, Domenico Franco Merlo, Paolo Bruzzi, Ignazia La Torre, Matteo Ceccarelli, Gbenga Kazeem, et al.

    This open-label study compared docetaxel/gemcitabine vs. paclitaxel/gemcitabine and a weekly (W) vs. 3-weekly (3 W) schedule in metastatic breast cancer (MBC).


  • Capecitabine Plus Weekly Oxaliplatin in Gastrointestinal Tumors

    by Chiara Carlomagno, Michele Orditura, Stefano Pepe, Ferdinando De Vita, Carmela Romano, Fortunato Ciardiello, Claudia Ferrara, Erika Martinelli, Roberto Bianco, Gaetano Aurilio, et al.

    Objective: To investigate the maximum tolerated dose (MTD) and the dose-limiting toxicity (DLT) of capecitabine plus oxaliplatin. Materials and Methods: Oxaliplatin was given by 2-hour iv infusion on days 1 and 8, and capecitabine was given orally, from day 1 to 14, every 3 weeks. We tested 4 levels of doses: 1) capecitabine 1650 mg/m2 + oxaliplatin 50 mg/m2; 2) capecitabine 2000 mg/m2 + oxaliplatin 50 mg/m2; 3) capecitabine 2000 mg/m2 + oxaliplatin 60 mg/m2; and 4) capecitabine 2500 mg/m2 + oxaliplatin 60 mg/m2. Patients with gastrointestinal neoplasm were eligible for the study. Results: Thirty-two patients were enrolled. At dose level 4, 3 patients had unacceptable toxicity (grade 3 diarrhea, grade 4 diarrhea, and grade 3 mucositis, respectively), thus, level 4 was the MTD. Apart from DLT, overall toxicity was mild: grade ≥3 nonhematological toxicity occurred in 3 patients, and hematological toxicity was sporadic. Conclusion: This study demonstrates that clinically relevant doses of capecitabine (2000 mg/m2 from day 1 to 14) plus oxaliplatin (60 mg/m2 on days 1 and 8) every 3 weeks can be given without causing unacceptable toxicity.


  • Open Access

    Modulation of 5-fluorouracil as adjuvant systemic chemotherapy in colorectal cancer: the IGCS-COL multicentre, randomised, phase III study

    by S De Placido, M Lopez, C Carlomagno, G Paoletti, S Palazzo, L Manzione, C Iannace, G P Ianniello, F De Vita, C Ficorella, et al.